Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Publ. Version/Full Text Volltext
DOI
PMC
 |
Open Access Gold |
as soon as is submitted to ZB.
Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes.
Proc. Natl. Acad. Sci. U.S.A. 103, 14188-14193 (2006)
EBV is a paradigm for human tumor viruses because, although it infects most people benignly, it also can cause a variety of cancers. Both in vivo and in vitro, EBV infects B lymphocytes in G0, induces them to become blasts, and can maintain their proliferation in cell culture or in vivo as tumors. How EBV succeeds in these contrasting cellular environments in expressing its genes that control the host has not been explained. We have genetically dissected the EBV nuclear antigen 1 (EBNA1) gene that is required for replication of the viral genome, to elucidate its possible role in the transcription of viral genes. Strikingly, EBNA1 is essential to drive transcription of EBV's transforming genes after infection of primary B lymphocytes.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
10.231
0.000
104
108
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
transcription; regulation; high-mobility group A protein; HMGA1a; EPSTEIN-BARR-VIRUS; LYMPHOBLASTOID CELL-LINES; LATENT MEMBRANE-PROTEIN-1; DNA-REPLICATION; INITIAL-STAGES; C-PROMOTER; B-CELLS; INFECTION; EBNA-1; ORIP
Language
english
Publication Year
2006
HGF-reported in Year
2006
ISSN (print) / ISBN
0027-8424
e-ISSN
1091-6490
Quellenangaben
Volume: 103,
Issue: 38,
Pages: 14188-14193
Publisher
National Academy of Sciences
Reviewing status
Peer reviewed
Institute(s)
Research Unit Gene Vector (AGV)
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Immune Response and Infection
PSP Element(s)
G-501500-001
PubMed ID
16966603
WOS ID
000240746600051
Scopus ID
33749039167
Erfassungsdatum
2006-11-06